Follow up Protocol to the Open Label Phase I/II Study OPN-305-106: A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line and First-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)

Trial Profile

Follow up Protocol to the Open Label Phase I/II Study OPN-305-106: A Prospective, Open Label Phase I/II Study to Assess the Safety and Efficacy of Cycles of Intravenously Infused Doses of OPN-305 in Second-line and First-line Lower (Low and Intermediate-1) Risk Myelodysplastic Syndrome (MDS)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 12 Apr 2018

At a glance

  • Drugs OPN 305 (Primary)
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Opsona Therapeutics
  • Most Recent Events

    • 05 Apr 2018 Status changed from not yet recruiting to recruiting.
    • 05 Apr 2018 Planned End Date changed from 1 Apr 2019 to 1 Jul 2019.
    • 05 Apr 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top